Prescriptive changes for price reduction of older medicines

4 December 2023 - Changes to the Dental and Pharmaceutical Benefits Agency's regulations and general advice on the pricing of ...

Read more →

Health economic assessment of Beyfortus for the prevention of lower respiratory tract disease caused by respiratory syncytial virus

18 October 2023 - TLV has prepared a health economic assessment for the regions for the medicine Beyfortus (nirsevimab).  ...

Read more →

Health economic assessment of Enhertu in breast cancer

13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions.  ...

Read more →

Patient access to medicines for rare health conditions at sustainable costs can be strengthened

2 October 2023 - The Swedish Dental and Medicines Benefits Agency, TLV, today submits a report to the government on how ...

Read more →

TLV believes that the requirements for evidence in new EU legislation must be strengthened

9 October 2023 - The European Commission's proposal for a new regulation and directive has a decisive impact on the quality ...

Read more →

New payment models are needed to finance new advanced treatments

29 September 2023 - Pricing and subsidy methods and processes need to be developed to address the challenges that arise when ...

Read more →

TLV is tasked with carrying out health economic assessments of new drugs against cancer

4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...

Read more →

Imbruvica is included in the high-cost protection with a changed benefit limitation

19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...

Read more →

More measures are needed to curb the development cost of pharmaceuticals

16 June 2023 - There are more and more new drugs, and more people are receiving treatment for their illnesses. At ...

Read more →

Health economic assessment of Pluvicto in advanced prostate cancer

12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan).  ...

Read more →

The Supreme Administrative Court did not test Mayzent

12 June 2023 - The Supreme Administrative Court decided on 3 May not to grant a review permit for Mayzent.  ...

Read more →

The FINOSE collaboration is extended and strengthened by the entry of the Danish Medicines Council

11 May 2023 - On 10 May 2023, the Nordic HTA collaboration FINOSE was extended for another three years and the ...

Read more →

TLV has decided on an increase in ceiling prices

12 April 2023 - TLV has decided to increase ceiling prices in certain package size groups. The decision to raise ceiling ...

Read more →

TLV reconsiders the subsidy of Lumykras (sotorasib)

4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...

Read more →

Survey on patients' access to medicines for the treatment of rare health conditions

31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...

Read more →